NEWS

Xenikos partners with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) to conduct a U.S.-based Phase 3 trial to test T-Guard(R) in acute graft-versus-host disease

Gentherapie verdient moderne regels

Nederland loopt investeringen voor gentherapie mis

Xenikos announces data from phase I/II trial with T-Guard™ for treatment of steroid-resistant acute GVHD presented at ASH Annual Meeting

APTAMER GROUP LTD SECURES $ 2.2 M SERIES A INVESTMENT